Clinical trials: gemcitabine hydrochloride
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or…
- Trial name
- NCT04442022
- Testing
- Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy)
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 501 people
- Sponsor
- Karyopharm Therapeutics Inc
Mucinous Pancreatic Cysts
The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts
The purpose of this study is to evaluate the efficacy of a chemotherapeutic cocktail with or without prior ethanol lavage for ablation of premalignant pancreatic cysts using endoscopic ultrasound-guided fine needle injection…
- Trial name
- NCT01475331
- Testing
- Ethanol, Normal Saline, Chemotherapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Milton S. Hershey Medical Center
Locally Advanced Pancreatic Ductal Adenocarcinoma
AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC
A prospective, single-arm, exploratory phase II clinical study evaluating the efficacy of Gemcitabine and Nab-palitaxe combined with Cadonilimab sequential short-course radiotherapy in the treatment of patients with locally…
- Trial name
- NCT06472037
- Testing
- Cadonilimab, Gemcitabine, Nab-Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer (NSCLC)
Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab
RATIONALE: Classically the evaluation of response in lung cancer has been based in comparing pre \& post treatment tumour volume by means of studying changes in the diameter of the selected target lesions by RECIST.
- Trial name
- NCT02316327
- Testing
- gemcitabine, cisplatin and bevacizumab
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Unspecified Adult Solid Tumor, Protocol Specific
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth…
- Trial name
- NCT00483366
- Testing
- capecitabine, gemcitabine hydrochloride, imatinib mesylate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Lung Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy used high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003803
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 17 sites in Belgium, France and 3 more
- Volunteers
- 158 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ewing's Sarcoma
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Tumors of the Ewing sarcoma family (ES) affect children, adolescents and young adults. The reported incidence is 0.6 cases per million inhabitants every year.
- Trial name
- NCT01696669
- Testing
- Chemotherapy, Surgery, Radiotherapy
- Where
- 9 sites in Spain
- Volunteers
- 43 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
This randomized phase II trial studies the side effects and how well giving monoclonal antibody SGN-30 together with combination chemotherapy works in treating patients with Hodgkin lymphoma that has returned after a period of…
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00337194
- Testing
- monoclonal antibody SGN-30, vinorelbine tartrate, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Intrahepatic Cholangiocarcinoma
GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC
This study aimed to preliminarily evaluate the clinical efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of gemcitabine and oxaliplatin (GEMOX) plus systemic gemcitabine chemotherapy (GEM-SYS) combined with…
- Trial name
- NCT06505486
- Testing
- Gemcitabine-Oxaliplatin Regimen
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non-small Cell Lung Cancer
Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer
Stage IIIA NSCLC represents a relatively heterogeneous group of pts with ipsilateral mediastinal (N2) lymph node involvement. The relative roles of treatment modalities are not clearly defined.
- Trial name
- EMERGING (NCT01407822)
- Testing
- Erlotinib, Gemcitabine/cisplatin
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Guangdong Association of Clinical Trials
Sarcoma
Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma
Soft tissue sarcomas (STS) are a group of rare mesenchymal neoplasms affecting all ages. STS most commonly present as localised disease but despite surgery and adjuvant treatment more than half of patients will develop recurrent…
- Trial name
- GEMMK (NCT03123276)
- Testing
- Pembrolizumab, Gemcitabine
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Unresectable Cholangiocarcinoma
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.
A prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases.
- Trial name
- NCT04378023
- Testing
- Neoadjuvant Chemo-radiotherapy, Liver Transplantation
- Where
- Spain
- Volunteers
- 34 people
- Sponsor
- Hospital Vall d'Hebron
Liver Transplantation, Hepatocellular Carcinoma
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.
- Conditions
- Liver Transplantation, Hepatocellular Carcinoma, Tumor Recurrence and Metastasis, Survival
- Trial name
- NCT01125020
- Testing
- gemcitabine and oxaliplatin, doxorubicin, 5-Fu and cisplatin
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Resectable Pancreatic Carcinoma
Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma
This phase II study is to evaluate the efficacy of preoperative chemoradiotherapy with gemcitabine (400mg/m2, weekly) for resectable pancreatic cancer.
- Trial name
- NCT01333124
- Testing
- chemoradiotherapy with Gemcitabine, Radiation: chemoradiotherapy with Gemcitabine
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- National Cancer Center, Korea
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy
Second-line therapy with Nal-IRI after failure gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy
- Trial name
- PREDICT (NCT03468335)
- Testing
- Irinotecan Liposomal Injection [Onivyde]
- Where
- 35 sites in Germany
- Volunteers
- 151 people
- Sponsor
- AIO-Studien-gGmbH
Pancreatic Cancer
NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery in patients with resectable or borderline resectable pancreatic adenocarcinoma.
- Trial name
- NEO-IMPACT (NCT06094140)
- Testing
- Durvalumab, Oxaliplatin, Irinotecan
- Where
- 3 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Ovarian Cancer
Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003449
- Testing
- dexamethasone, gemcitabine hydrochloride, paclitaxel
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Non-Small Cell Lung Cancer
Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.
- Trial name
- NCT00423449
- Testing
- vorinostat, Gemcitabine, Platinum-based agent
- Volunteers
- 61 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
This phase II trial will study the effectiveness and toxicity of sequential high dose MVAC followed by gemcitabine and cisplatin, as first line treatment in patients with locally advanced or metastatic bladder cancer.
- Trial name
- NCT00635726
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 7 sites in Greece
- Volunteers
- 41 people
- Sponsor
- Hellenic Oncology Research Group
Treatment Refusal
PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival.
- Trial name
- NCT02705508
- Testing
- Gemcitabine, etoposide, Pegaspargase
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.